Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.31B +14.2% |
| Revenue (ttm) | 156.04M +158.9% |
| Net Income | -86.52M |
| EPS | -0.84 |
| Shares Out | 99.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,239,238 |
| Open | 23.41 |
| Previous Close | 23.22 |
| Day's Range | 22.67 - 23.65 |
| 52-Week Range | 20.23 - 38.26 |
| Beta | 2.23 |
| Analysts | Strong Buy |
| Price Target | 52.15 (+125.37%) |
| Earnings Date | Nov 3, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $52.15, which is an increase of 125.37% from the latest price.
News
Beam Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Gene editing programs are advancing with strong clinical data in AATD, PKU, and sickle cell, leveraging base editing and integrated manufacturing. BEAM-302 shows durable efficacy and safety, while BEAM-304 and risto-cel are positioned for rapid development and commercial impact.
Beam Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant pipeline progress includes pivotal trials for AATD and sickle cell, with strong clinical data and regulatory alignment for accelerated approval. The platform enables rapid expansion to new indications, with a robust commercial and financial outlook supporting multiple blockbuster opportunities.
Beam Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Base editing platform enables precise, durable genetic corrections for multiple diseases, with recent data showing strong efficacy and safety in alpha-1 antitrypsin deficiency. Regulatory alignment supports accelerated approval, and commercial plans are advancing for sickle cell and other pipeline programs.
Beam Therapeutics Transcript: Status update
Updated BEAM-302 data show durable, functional AAT restoration and significant reduction in disease-driving Z-AAT and Z-polymers, with a favorable safety profile and strong global enrollment in the pivotal cohort. Regulatory alignment supports an accelerated approval pathway, and financial resources are robust.
Beam Therapeutics Press release: Status update
Beam Therapeutics issued a press release on September 8, 2026, disclosing material business information to investors.
Beam Therapeutics Slides: Status update
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo...
Beam Therapeutics Slides: European Respiratory Society Congress presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 7, 2026.
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the app...
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics Earnings release: Q2 2026
Beam Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q2 2026
Beam Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Beam Therapeutics Slides: Corporate presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Slides: Conference presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging...
Beam Therapeutics Transcript: AGM 2026
The meeting featured the election of three directors, ratification of Deloitte as auditor, and approval of executive compensation, with all proposals passing. No shareholder questions were raised, and final vote results will be filed in a Form 8-K.
Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Base editing programs show strong efficacy and safety in hematology and liver diseases, with lead assets advancing toward regulatory filings and broader patient reach. Accelerated approval is supported by robust biomarker data, and pricing will reflect long-term value.
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po...
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ...